One or Two Immune Checkpoint Inhibitors?
Authors:
- 1 December 2019
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 36 (6) , 579-581
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2019
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2019
- Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationAnnals of Oncology, 2019
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialJournal of Clinical Oncology, 2019
- Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”Annals of Oncology, 2019
- Is earlier better for melanoma checkpoint blockade?Nature Medicine, 2018
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2018
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010